MORF News and Press, Morphic Holding Inc. From 04/29/21

Morphic (MORF): Q1 GAAP EPS of -$0.63 misses by $0.09.Revenue of $3.26M (-41.8% Y/Y) misses by $5.07M.Press Release For further details see: Morphic EPS misses by $0.09, misses on revenue

Expanded research and development collaboration with Janssen for third integrin program Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 Received acceptance to present full MORF-057 Phase 1 data set at the ECCO’21 Virtual Congress...

WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to its Board of Directors. Ms. Gray is an accomplished leader in healthcare finance an...

On March 1, Morphic Holding 's (NASDAQ: MORF) stock more than doubled after the company announced interim phase 1 data on its experimental therapy, MORF-057. That's a pretty significant pop for an under-the-radar biotech, especially based on data that comes from so early i...

First data from oral αvβ8 program demonstrate potent anti-tumor response through TGFβ pathway Combination with checkpoint inhibitor showed efficacy in checkpoint-resistant models of breast cancer and induced a lasting anti-tumor effect WALTHAM, Mass., ...

Insider buying decreased significantly last week. Notable Insider Buys: News Corporation, Morphic Holding, Inc., Dropbox, Inc., Lions Gate Entertainment Corp., and OPKO Health, Inc. Notable Insider Sells: Snowflake Inc., The Carlyle Group Inc., Facebook, Inc., WW International, In...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks powered higher after a slow start Friday as U.S. Treasury yields fell back from early highs. All major groups in the S&P 500 finis...

Morphic (MORF) has priced its upsized public offering of 3.5M common shares at $70.00/share, for expected gross proceeds of ~$245M (from $200M).Underwriters' over-allotment is an additional 525K shares. Net proceeds will be used to fund research, clinical and process development and manufactu...

WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering o...

After more than doubling on Monday, Morphic Holding 's (NASDAQ: MORF) shares are taking a beating on Tuesday. As of 11:10 a.m. EST, the biopharmaceutical company's stock is down by 13.6%. There are two likely explanations for Morphic Holding's losses on the stock market today. First...